10-Q: Exicure Q2: Biotech Pivot, Cash Concerns, Legal Settlements

Exicure, Inc. reports a net income for the six months ended June 30, 2025, driven by a significant lease termination gain, but faces substantial doubt about its ability to continue as a going concern due to insufficient cash.

Summary

• Acquired GPCR Therapeutics USA Inc. (GPCR USA) on January 19, 2025, for $7.881 million, including cash, equity, and contingent consideration.
• GPCR USA has an ongoing Phase 2 clinical trial for GPC-100 in Multiple Myeloma patients, with administration to 20 patients completed in Q2 2025, and results aimed for Q4 2025.
• Formed KC Creation Co., Ltd., a wholly-owned South Korean subsidiary, on March 26, 2025, to pursue collaborations, ESG trends (eco-friendly renewable energy), and diversification into Korean entertainment content.
• Reported a net income of $389,000 for the six months ended June 30, 2025, primarily due to a $5.974 million gain on early lease termination.
• Incurred a net loss of $2.621 million for the three months ended June 30, 2025, compared to a net loss of $600,000 for the same period in 2024.
• Cash and cash equivalents decreased from $12.508 million at December 31, 2024, to $7.858 million at June 30, 2025.
• Management believes existing cash is insufficient to fund operations for the next 12 months, raising substantial doubt about the ability to continue as a going concern.
• Research and development (R&D) expenses increased to $1.743 million for the six months ended June 30, 2025 (from $0 in 2024), reflecting the GPCR USA acquisition.
• General and administrative (G&A) expenses increased by 45% to $3.731 million for the six months ended June 30, 2025.
• Settled a securities class action lawsuit for $5.625 million, fully covered by insurance, with a $1.0 million self-insured retention paid.
• Accrued $411,000 in registration delay payments due to not filing a registration statement by the deadline for previous stock purchases.
• Identified material weaknesses in internal control over financial reporting related to management's review of non-routine activities and the design/implementation of controls around accounting and IT processes.

Sentiment

Score: 2

Explanation: Despite a reported net income for the six-month period, this was due to a one-time gain. The company faces severe liquidity issues, explicitly stating 'substantial doubt about its ability to continue as a going concern' and the potential for bankruptcy. Operational cash burn is increasing, and while new ventures are mentioned, their revenue generation is uncertain. The identified material weaknesses in internal controls further compound the negative sentiment.

Positives

• Achieved a net income of $389,000 for the six months ended June 30, 2025, primarily due to a $5.974 million gain on early lease termination.
• Successfully acquired GPCR Therapeutics USA Inc., expanding into new biotechnology areas with an ongoing Phase 2 clinical trial.
• Completed administration of GPC-100 to 20 patients in the Phase 2 clinical trial during Q2 2025, with results expected in Q4 2025.
• Formed a new South Korean subsidiary, KC Creation Co., Ltd., to explore new growth strategies including bio-platform collaborations, ESG initiatives, and Korean entertainment content.
• Settled a securities class action lawsuit for $5.625 million, which is fully covered by insurance, limiting direct financial impact to a $1.0 million self-insured retention.
• Received a waiver for a $191,000 penalty amount owed for registration rights delay from DGP.

Negatives

• Reported a net loss of $2.621 million for the three months ended June 30, 2025, a significant increase from $600,000 loss in the prior year quarter.
• Cash and cash equivalents decreased by $4.650 million to $7.858 million as of June 30, 2025, from $12.508 million at December 31, 2024.
• Management believes existing cash and cash equivalents are insufficient to fund operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• Incurred increased operating expenses, with R&D rising to $1.743 million and G&A increasing by 45% to $3.731 million for the six months ended June 30, 2025.
• Accrued $411,000 in registration delay payments due to failure to file a registration statement by the deadline for previous stock purchase agreements.
• Recognized a loss of $159,000 for the three months ended June 30, 2025, and $295,000 for the six months ended June 30, 2025, related to the change in fair value of contingent liability.
• Identified material weaknesses in internal control over financial reporting, specifically regarding management's review of non-routine activities and the design/implementation of controls around accounting and IT processes.

Risks

• Substantial uncertainties regarding the exploration of strategic alternatives, including identifying partners, consummating transactions, obtaining sufficient funding, and generating stockholder value.
• Inability to raise additional capital needed to fund operations and strategic alternatives, particularly given the current lack of a revenue source and substantial doubt about the ability to continue as a going concern.
• Risk of delisting from The Nasdaq Capital Market due to inability to maintain minimum stockholders' equity, stock price, and compliance with governance requirements.
• Potential for unexpected costs, liabilities, and/or delays from any strategic plan or alternative, which may not deliver anticipated benefits.
• Inaccuracy of estimates for expenses, cash use, future cash needs, ongoing losses, and capital requirements.
• Uncertainty about investor and business partner reaction to recent changes in control, board, and management composition, and the ability of new leadership to earn confidence despite limited experience with U.S. public companies.
• Potential turnover of senior management and inability to attract/retain qualified personnel, leading to significant continuity risk and impaired ability to raise capital or execute strategic alternatives.
• Challenges in complying with all applicable laws, especially with recent turnover, significant reductions in force, limited resources, and potential entry into new business areas.
• Difficulty for investors to assess operations primarily within subsidiaries whose performance is consolidated.
• Ability to obtain and maintain intellectual property protection and operate without infringing others' IP rights.
• Impact of macroeconomic conditions (global inflation, central bank actions, capital market/bank instability, exchange rate fluctuations, supply chain disruptions, energy/fuel prices) and geopolitical events (conflicts in Ukraine, Russia, Middle East).
• Impact of government laws and regulations, including taxes and tariffs.
• Litigation and claims, including defense and settlement costs, and diversion of management resources.

Future Outlook

The company aims to announce GPCR USA clinical trial results during the fourth quarter of 2025. It expects to incur significant expenses and negative cash flows for the foreseeable future, and management believes existing cash and cash equivalents are insufficient to fund operating expenses for the next twelve months, necessitating additional financing primarily through equity offerings. Future capital requirements are uncertain and depend on strategic alternatives, litigation outcomes, and macroeconomic conditions. The company's continued viability is dependent on its ability to raise additional capital.

Management Comments

• Management believes that, given the current cash position, operating plans and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about the ability to continue as a going concern within one year after the date these financial statements are issued.
• Additional financing will be needed to fund ongoing operations, support of GPCR USA's operations, and exploration of strategic alternatives and pursuing any alternatives that management identifies.
• If we are unable to raise capital, the Company may seek bankruptcy protection and/or cease operations in the near term, which may result in the Company's stockholders receiving no or very little value in respect of their shares of the Company's common stock.
• We expect to seek financing through equity offerings. However, it may be difficult to obtain financing given the Company's current condition and uncertainty over its future direction.
• We are evaluating the material weakness and are developing a plan of remediation to strengthen the effectiveness of the design and operation of our internal control environment.

Industry Context

The company is undergoing a significant strategic pivot, transitioning from an early-stage biotechnology focus on nucleic acid therapies to a diversified model. This involves acquiring new biotechnology assets (GPCR USA's Phase 2 blood cancer trial) while also venturing into non-biotech sectors such as eco-friendly renewable energy and Korean entertainment content through its new South Korean subsidiary, KC Creation. This broad diversification is unusual for a traditional biotech firm and suggests a shift towards a holding company or diversified investment strategy, seeking new revenue streams beyond its historical core. The move into ESG and entertainment indicates a departure from conventional biotech industry trends.

Comparison to Industry Standards

• Direct comparison to industry standards is challenging given the company's significant strategic pivot and explicit 'going concern' warning.
• For a biotechnology company, having a Phase 2 clinical trial (GPC-100 for Multiple Myeloma) is a positive development, but the company's overall financial instability and lack of consistent revenue make it difficult to benchmark against established biotech firms.
• The diversification into renewable energy and entertainment content is highly unusual for a company previously focused on nucleic acid therapies, making traditional industry comparisons irrelevant for the consolidated entity.
• The 'going concern' warning is a critical indicator of financial distress, placing the company significantly below industry standards for financial stability and operational viability.
• The identified material weaknesses in internal control over financial reporting also suggest a lack of robust financial governance compared to well-established public companies.

Management Changes

Corporate Governance

Legal Proceedings

• Securities Class Action (Colwell v. Exicure, Inc. et al.): Final judgment approving a $5.625 million settlement was entered on January 13, 2025. The settlement is fully covered by insurance, but the company is liable for a $1.0 million self-insured retention, which it agreed to remit on July 29, 2025.
• Stockholder Derivative Lawsuits (Puri v. Giljohann, et al.; Sim v. Giljohann, et al.; Stourbridge Investments LLC v. Exicure, Inc. et al.): Three related lawsuits and a demand letter are currently stayed. An agreement in principle for global resolutions was reached around July 22, 2025, subject to formal agreement and court approval.
• Former Employee Complaint: A complaint filed on October 3, 2023, related to a former employee's separation. The matter is in the discovery phase, with ongoing work to address alleged discovery deficiencies and anticipated depositions.

Related Party Transactions

• Consulting Agreement with Alta Companies LTD (Paul Kang, former CEO/director) for transitional consulting services, with an initial payment of $99,000 and monthly payments of $12,500 starting February 2025.
• Korea Lease with YOOSOO Co., Ltd., a related party of Exicure HiTron Inc., for a 24-month lease with a security deposit but no lease payments.
• DGP Co., Ltd. (DGP), a related party, provided a $700,000 promissory note on June 3, 2024, which was converted into 237,223 shares of common stock on September 12, 2024. DGP also waived a $191,000 penalty amount owed for registration rights delay.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity offerings and the explicit warning of 'substantial doubt about its ability to continue as a going concern' which could lead to 'no or very little value' for shares.
• Employees may experience uncertainty due to past significant reductions in force and potential future turnover of senior management.
• Customers and partners may be impacted by the company's financial instability and strategic pivot, potentially affecting existing or future collaborations.
• Creditors face increased risk due to the 'going concern' warning and the company's stated insufficient liquidity.
• Regulatory bodies, such as Nasdaq, have noted compliance challenges, including a past delinquency notice for a filing and identified material weaknesses in internal controls.

Next Steps

• Aim to announce GPCR USA clinical trial results during the fourth quarter of 2025.
• Continue exploration of strategic alternatives (private company acquisitions, raising additional capital, strategic partnerships, other arrangements).
• Seek additional financing, primarily through equity offerings.
• Remediate identified material weaknesses in internal control over financial reporting, including enhancing review procedures and potentially adding personnel.
• Continue working through alleged discovery deficiencies in the former employee litigation and anticipate deposing the plaintiff and witnesses.
• Memorialize and seek court approval for the agreement in principle for global resolutions of the Derivative Complaints and Demand Letter.

Key Dates

Recommendation

The company explicitly states 'substantial doubt about its ability to continue as a going concern' and warns of potential bankruptcy, which could result in 'no or very little value' for stockholders. While there's a one-time gain from lease termination, operational cash burn is high, and the strategic pivot into diverse, non-core areas (renewable energy, entertainment) without clear revenue generation or expertise adds significant uncertainty. Material weaknesses in internal controls further undermine confidence. The risks far outweigh any potential upside from the early-stage biotech asset or new ventures.

Keywords

Biotechnology, SEC Filing, 10-Q, Financial Report, Clinical Trials, GPCR Therapeutics, Multiple Myeloma, Strategic Alternatives, Going Concern, Nasdaq Listing, Capital Raise, Corporate Governance, Legal Proceedings, Financial Performance, Biopharmaceutical, GPC-100, Korean Bio-platform, ESG, Entertainment Content